Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

SLND Versus Non-Dissection Following ESD for T1a Stage Esophageal Squamous Cell Carcinoma

Not Applicable

Not yet recruiting

Conditions: Esophageal Cancer

First Posted Date: 2025-05-20

Last Posted Date: 2025-05-20

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 102

Registration Number: NCT06979986

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 3

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: Tislelizumab
Drug: Oxaliplatin injection
Drug: Levo-Leucovorin
Drug: 5-fluorouracil
Drug: Paclitaxel

First Posted Date: 2025-01-27

Last Posted Date: 2025-01-27

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 269

Registration Number: NCT06793917

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

Phase 2

Not yet recruiting

Conditions: Colorectal Cancer Liver Metastasis

Interventions: Radiation: Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy
Drug: Bevacizumab
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Sintilimab

First Posted Date: 2025-01-23

Last Posted Date: 2025-01-23

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 35

Registration Number: NCT06788171

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: Small Cell Lung Cancer Extensive Stage

Interventions: Drug: Apatinib
Drug: Adebrelimab
Drug: Etoposide Injection
Drug: Carboplatin Injection

First Posted Date: 2025-01-22

Last Posted Date: 2025-01-22

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 34

Registration Number: NCT06786312

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
Fujian Provincial Hospital, Fuzhou, Fujian, China
🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

and more 1 locations

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

Phase 2

Not yet recruiting

Conditions: Locally Advanced Rectal Cancer With Liver Metastases

Interventions: Radiation: Short course radiotherapy
Drug: Capecitabine
Drug: Oxaliplatin
Drug: QL1706

First Posted Date: 2025-01-22

Last Posted Date: 2025-01-27

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 42

Registration Number: NCT06787183

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer

Phase 3

Not yet recruiting

Conditions: Nasopharyngeal Carcinoma

First Posted Date: 2025-01-15

Last Posted Date: 2025-01-15

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 474

Registration Number: NCT06775756

Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal Carcinoma

Not Applicable

Not yet recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Behavioral: Nurse-led intervention

First Posted Date: 2024-08-27

Last Posted Date: 2024-10-16

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 250

Registration Number: NCT06572293

SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma
SBRT
Immune Checkpoint Blockade
Tyrosine Kinase Inhibitor

Interventions: Drug: adbelimumab
Procedure: SBRT
Drug: apatinib

First Posted Date: 2024-08-06

Last Posted Date: 2024-08-06

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 80

Registration Number: NCT06538935

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

Phase 2

Not yet recruiting

Conditions: Liver Metastases of Colorectal Cancer

Interventions: Drug: Capecitabine
Drug: Oxaliplatin
Drug: Cetuximab
Drug: Leucovorin
Drug: 5-FU

First Posted Date: 2024-07-08

Last Posted Date: 2024-07-08

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 33

Registration Number: NCT06490913

Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: sintilimab，programmed death 1 monoclonal antibody

First Posted Date: 2024-06-21

Last Posted Date: 2024-06-21

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT06468670

Home Terms & Conditions Privacy Policy